More than 40 organizations, including the AHA, today urged House and Senate leaders to swiftly pass the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974/H.R. 2212). The legislation would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. “The CREATES Act is a narrowly targeted, bipartisan, pro-competition and market-based solution to these abuses that cost patients, job-creators and taxpayers billions of dollars each year,” the letter states. “…We thank the bipartisan, bicameral sponsors of this important legislation for the work that they have done to, in the words of FDA Commissioner Scott Gottlieb, ‘end the shenanigans’ by certain brand name companies, and we strongly encourage Congress to pass the CREATES Act without delay.”

Related News Articles

Headline
The House of Representatives last night voted 419-6 to pass legislation (H.R. 748) that would repeal the 40% excise tax on high-value employer-sponsored health…
Headline
The ERISA Industry Committee has withdrawn its support for legislation approved yesterday by the House Energy and Commerce Committee to address surprise…
Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Headline
Congress should pass legislation that would protect patients from surprise medical bills; preserve the ability of providers and insurers to negotiate private…
Headline
The Centers for Medicare & Medicaid Services yesterday released a proposed rule that would revise certain requirements for long-term care facilities.
Headline
The House Energy and Commerce Subcommittee on Health today passed the No Surprises Act (H.R. 3630), bipartisan legislation that would prohibit balance billing…